INFLAMMATION AT THE INTERFACE OF ATHEROSCLEROSIS, CKD, AND HF (AS-105)

Saturday, October 28, 2023

07:15 – 08:15 EST

Location: Palais, 517D

Target Audience: Cardiologists, Internists, Family physicians, Nephrologists

Co-Chair : AS(s)

Louise Moist

Nephrologist, Professor of Medicine and Epidemiology
LHSC
Western University
Subodh Verma, MD, PhD (he/him/his)

Cardiac Surgeon
CSCS
University of Toronto

Presenter : AS(s)

Anique Ducharme, MD (she/her/hers)

Cardiologist
CCS, CCTN, CHFS, CANCARE
University of Montreal
PR

Paul Ridker

Canadian Society of Cardiovascular Nuclear and CT Imaging

Disclosure(s):

Subodh Verma, MD, PhD: Amarin: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Amgen: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); AstraZeneca: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Bayer: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Boehringer-Ingelheim: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Canadian Medical and Surgical Knowledge Translation Research Group: Speaker/Honoraria (Ongoing); Eli Lilly: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); HLS Therapeutics: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Janssen: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Novartis: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Novo Nordisk: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Pfizer: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); PhaseBio: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Terminated, February 17, 2023), Speaker/Honoraria (Terminated, February 17, 2023); S&L Solutions: Speaker/Honoraria (Ongoing); Sanofi: Speaker/Honoraria (Ongoing)

Learning Objectives / Objectifs d'apprentissage:

At the end of this session participants will be able to / Au terme de cette conférence, vous serez:

describe the cumulative evidence supporting the role of inflammation and HSCRP in ASCVD, CKD, and heart failure;
articulate the role of residual inflammatory risk and HSCRP in predicting risk; and
understand how ongoing clinical trials may impact treatment choices in the future.

This program was co-developed by the Canadian Cardiovascular Society and Novo Nordisk Canada and was planned to achieve scientific integrity, objectivity, and balance.

Session Description:In this accredited symposium, a panel of experts in cardiology, cardiac surgery, and nephrology will discuss the role of systemic inflammation, including the involvement of the Il-6 pathway, in the management of residual risk in ASCVD, heart failure, and CKD.